A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
Condition: Large B-cell Lymphoma · Lymphoma, B-Cell · Relapsed Non-Hodgkin Lymphoma · Sponsor: Lyell Immunopharma, Inc.
About this study
This Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-targeting CD19/CD20 CAR T-cell therapy, with investigator's choice of CD19 CAR T-cell therapy in patients with relapsed or refractory large B-cell lymphoma in the second-line setting.
This description comes directly from the study's public registry record.
Talk to the study team
David Shook, MD · 000-000-0000 · clinicaltrials@lyell.com
Mary Lessig, MS · 000-000-0000 · clinicaltrials@lyell.com
Always discuss trial participation with your own doctor first.
Locations (36)
| Banner MD Anderson Cancer Center | Gilbert, Arizona, United States | Recruiting |
| Honor Health | Scottsdale, Arizona, United States | Recruiting |
| Mayo Clinic Arizona | Scottsdale, Arizona, United States | Recruiting |
| University of Arkansas | Little Rock, Arkansas, United States | Not Yet Recruiting |
| Cedars-Sinai Medical Center | Los Angeles, California, United States | Recruiting |
| University of California, Los Angeles (UCLA) | Los Angeles, California, United States | Recruiting |
| University of California, Irvine | Orange, California, United States | Recruiting |
| University of Colorado | Aurora, Colorado, United States | Recruiting |
| Colorado Blood Cancer Institute | Denver, Colorado, United States | Recruiting |
| MedStar Georgetown University Hospital | Washington D.C., District of Columbia, United States | Not Yet Recruiting |
| Mayo Clinic Florida | Jacksonville, Florida, United States | Recruiting |
| AdventHealth | Orlando, Florida, United States | Not Yet Recruiting |
+ 24 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07188558